Table 5 Baseline characteristics of the EPL and PBO groups in the intervention study.
Parameter | Placebo (n = 19) | Eplerenone (n = 20) | P |
|---|---|---|---|
SBP, mmHg | 132.1 ± 2.04 | 131.9 ± 2.31 | 0.886 |
DBP, mmHg | 76.3 ± 1.07 | 76.6 ± 1.46 | 0.509 |
eGFR, ml/min/1.73 m2 | 63.9 ± 3.73 | 65.2 ± 3.59 | 0.598 |
Serum creatinine, mg/dL | 0.91 ± 0.07 | 0.88 ± 0.06 | 0.610 |
Fasting blood sugar, mg/dL | 109.2 ± 3.1 | 111.7 ± 3.50 | 0.409 |
IRI, μU/mL | 12.1 ± 0.4 | 12.6 ± 3.0 | 0.642 |
Glycated albumin, % | 14.4 ± 0.36 | 15.0 ± 0.30 | 0.243 |
PAC, ng/dL | 18.9 ± 1.86 | 21.6 ± 2.16 | 0.315 |
Plasma active renin, pg/mL | 9.86 ± 1.97 | 10.7 ± 2.67 | 0.798 |
Serum potassium, mEq/L | 4.19 ± 0.08 | 4.17 ± 0.08 | 0.826 |
Urine α1-microglobulin/creatinine, mg/g | 7.41 ± 1.57 | 8.72 ± 1.48 | 0.354 |
Urine NAG/creatinine, IU/g | 7.25 ± 0.77 | 6.68 ± 0.88 | 0.373 |
Urine β2-microglobulin/creatinine, mg/g | 144.2 ± 22.8 | 262.0 ± 86.3 | 0.227 |
Urine protein/creatinine, g/g | 0.42 ± 0.12 | 0.47 ± 0.16 | 0.813 |
Cause of CKD | |||
Nephrosclerosis (%) | 11/19 (57.9%) | 14/20 (70.0%) | 0.515 |
Chronic glomerulonephritis (%) | 5/19 (26.3%) | 5/20 (25.0%) | 0.925 |
Diabetic nephropathy (%) | 2/19 (10.5%) | 1/20 (5.0%) | 0.605 |
Others (%) | 1/19 (5.3%) | 0/20 (0%) | 0.482 |
Antihypertensive medication | |||
ARB or ACEI (%) | 15/19 (78.9%) | 14/20 (70.0%) | 0.716 |
Calcium channel blocker (%) | 12/19 (63.2%) | 9/20 (45.0%) | 0.341 |
Diuretic (%) | 5/19 (26.3%) | 3/20 (15.0%) | 0.451 |
β-blocker (%) | 2/19 (10.5%) | 4/20 (20.0%) | 0.661 |
